Neeraj Agarwal hosts Atul Batra to discuss the CIPHER trial, a single-center phase 2 study of carboplatin AUC5 every three weeks in 39 patients with metastatic castration-resistant prostate cancer harboring somatic or germline HRR gene mutations who had progressed on an ARPI, docetaxel, or both.
|
